High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer-Reference-Cited by-同舟云学术

High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer

Published:2008-11 Issue:11 Volume:19 Page:1978-1980
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mir O.,Ropert S.,Alexandre J.,Lemare F.,Goldwasser F.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/11/1978/514788/mdn654.pdf

Reference9 articles.

1. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier;Stemmler;Anticancer Drugs,2007

2. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab;Platini;Lancet Oncol,2006

3. Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer;Stemmler;Oncol Rep,2006

4. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis;Laufman;Clin Breast Cancer,2001

5. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER-2 overexpressing metastatic breast cancer: a case report;Stemmler;Anticancer Drugs,2008

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review on the Efficacy and Safety of Intrathecal Administration of Novel Medications for Leptomeningeal Metastases in Solid Cancers;Current Medicinal Chemistry;2023-05-08

2. Therapies beyond Physiological Barriers and Drug Resistance: A Pilot Study and Review of the Literature Investigating If Intrathecal Trastuzumab and New Treatment Options Can Improve Oncologic Outcomes in Leptomeningeal Metastases from HER2-Positive Breast Cancer;Cancers;2023-04-27

3. Intrathecal treatments for leptomeningeal metastases;Cerebrospinal Fluid and Subarachnoid Space;2023

4. Intrathecal Chemotherapy for Central Nervous System Malignancy;Neuraxial Therapeutics;2023

5. Advances in the Management of Central Nervous System Metastases from Breast Cancer;International Journal of Molecular Sciences;2022-10-19